TRex Bio
TRexBio is a biotechnology company focused on developing revolutionary therapeutics by decoding human tissue immune biology. They utilize a proprietary platform to map Treg behavior and identify novel targets for therapeutic intervention, creating a broad portfolio of therapies that modulate the immune system to restore immune homeostasis. Their lead candidate, TRB-061, is designed to selectively activate tissue-licensed Tregs to address inflammatory and autoimmune conditions.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $84M
Date: 13-Nov-2024
Investors: Delos Capital, Avego BioScience Capital, Agent Capital, Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson, Alexandria Venture Investments, Polaris Partners
Markets: Biotechnology, Immunology, Therapeutics, Bioinformatics, Biopharma
HQ: South San Francisco, California, United States
Founded: 2018
Website: https://trex.bio/
LinkedIn: https://www.linkedin.com/company/trexbio-inc
Crunchbase: https://www.crunchbase.com/organization/trex-bio
Leave a Comment
Comments
No comments yet.